References

1. K.A. Nave and O. Boespflug-Tanguy, X-linked developmental defects of myelination: from mouse mutants to human genetic diseases, Neuroscientist 2, 33-43, (1996).

2. L.D. Hudson, J.Y. Garbern and J.A. Kamholz, Pelizaeus-Merzbacher disease, in: Myelin Biology and Disorders, vol. II, edited by R.A. Lazzarini (Elsevier, London), pp. 867-885, (2004)

3. S. Bonavita, R. Schiffmann, D.F. Moore, K. Frei, B. Choi, N. Patronas, A. Virta, O. Boespflug-Tanguy, and G. Tedeschi, Evidence for neuroaxonal injury in patients with proteolipid protein gene mutations, Neurology 56, 785-788 (2001).

4. J. Takanashi, K. Inoue, M. Tomita, A. Kurihara, F. Morita, H. Ikehira, S. Tanada, E. Yoshitome, and Y. Kohno, Brain N-acetylaspartate is elevated in Pelizaeus-Merzbacher disease with PLP1 duplication, Neurology 58, 237-241 (2002).

5. J.T. Coyle, The nagging question of the function of N-acetylaspartylglutamate. Neurobiol. Dis. 4, 231238, (1997).

6. P.J.W. Pouwels and J. Frahm, Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS, NMR Biomed. 10, 73-78, (1997).

7. L.M. Gehl, O.H. Saab, Y. Bzdega, B. Wroblewska, and J.H. Neale, Biosynthesis of NAAG by an enzyme-mediated process in rat central nervous system neurons and glia, J. Neurochem. 90, 989-997, (2004).

8. B. Stauch Slusher, M.B. Robinson, G. Tsai, M.L. Simmons, S.S. Richards, and JT Coyle. Rat brain N-acetylated a-linked acidic dipeptidase activity. Purification and immunological characterization, J. Biol. Chem. 265, 21297-21301, (1990).

9. T. Bzdega, S.L. Crowe, E.R. Ramadan, K.H. Sciarretta, R.T. Olszewski, O.A. Ojeifo, V.A. Rafalski, B. Wroblewska, and J.H. Neale, The cloning and characterization of a second brain enzyme with NAAG peptidase activity, J. Neurochem. 89, 627-635, (2004).

10. A.P. Burlina, V. Ferrari, P. Divry, W. Gradowska, C. Jakobs, M.J. Bennett, A.C. Sewell, C. Dionisi-Vici, and A.B. Burlina, N-acetylaspartylglutamate in Canavan disease: an adverse effector? Eur. J. Pediatr. 158, 406-409, (1999).

11. J.D. Rothstein, G. Tsai, R.W. Kuncl RW, L. Clawson, D.R. Cornblath, D.B. Drachman, A. Pestronk, B.L. Stauch, and J.T. Coyle, Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis, Ann. Neurol . 28, 18-25, (1990).

12. A.P. Burlina, V. Ferrari, L. Bonafe, and A.B. Burlina, Clinical and biochemical follow-up of a patient with Canavan disease, J. Inherit. Metab. Dis. 21(suppl. 2), 48, (1998).

13. N.I. Wolf, M.A.A.P. Willemsen, U.F. Engelke, M.S. van der Knaap, P.J.W. Pouwels, I. Harting, J. Zschocke, E.A. Sistermans, D. Rating, and R.A. Wevers, Severe hypomyelination associated with increased levels of N-acetylaspartylglutamate in CSF, Neurology 62, 1503-1508, (2004).

14. J.H. Neale, T. Bzdega, and B. Wroblewska. N-acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system, J. Neurochem. 75, 443-452, (2000).

15. A.P. Burlina, S.D. Skaper, M.R. Mazza, V. Ferrari, A. Leon, and A.B. Burlina, N-acetylaspartylglutamate selectively inhibits neuronal responses to N-methyl-D-aspartic acid in vitro. J. Neurochem. 63, 11741177, (1994).

16. W. Deng, H. Wang, P.A. Rosenberg, J.J. Volpe, and F.E. Jensen, Role of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and oxidative stress, Proc. Natl. Acad. Sci. 101, 7751-7756, (2004).

17. A.G. Thomas, J.J. Vornov, J.L. Olkowski, A.T. Merion and B.S. Slusher, N-acetylated a-linked acidic dipeptidase converts N-acetylaspartylglutamate from a neuroprotectant to a neurotoxin. J. Pharmacol. Exp. Therap. 295, 16-22, (2000).

18. G.D. Ghadge, B.S. Slusher, A. Bodner, M. Dal Canto, K. Wozniak, A.G. Thomas, C. Rojas, T. Tsukamoto, P. Majer, R.J. Miller, A.L. Monti and R.P. Roos, Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis, Proc. Natl. Acad. Sci. 100, 9554-9559, (2004).

19. I. Griffiths, M. Klugmann, T. Anderson , D. Yool, C. Thomson, M.H. Schwab, A. Schneider, F. Zimmermann, M. McCulloch, N. Nadon, and K.A. Nave, Axonal swellings and degeneration in mice lacking the major proteolipid of myelin, Science 280, 1610-1613, (1998).

20. A.P. Burlina, T. Aureli, F. Bracco, F. Conti, and L. Battistin, MR spectroscopy: a powerful tool for investigating brain function and neurological diseases, Neurochem. Res. 25, 1365-1372, (2000).

21. E. Martin, A. Capone, J. Schneider, J. Hennig, and T. Thiel, Absence of N-acetylaspartate in the human brain: impact on neurospectroscopy? Ann. Neurol. 49, 518-521, (2001).

22. E. Boltshauser, B. Schmitt, R.A. Wevers, U. Engelke, A.B. Burlina, and A.P. Burlina, Follow-up of a child with hypoacetylaspartia. Neuropediatrics 35, 255-258, (2004).

0 0

Post a comment